Search Results
Your search for ASCO matches 21586 pages
Showing 18051 - 18100Overdiagnosis of Breast Cancer: New Research Directions
Currently, one of the most challenging problems in oncology is to accurately predict whether neoplastic lesions detected by screening tests will progress. The focus on developing ever-more sensitive cancer screening tests has produced the clinical dilemma of overdiagnosis. Overdiagnosis occurs when ...
The Canadian National Breast Screening Trial Had So Many Flaws That Its Results Should Not Be Used to Guide Screening Recommendations
If a randomized, controlled trial of therapy for breast cancer was submitted for publication in which 1. The drug being tested was old and ineffective, and 2. prior to randomization, the women underwent a clinical breast examination and the study coordinators knew who had the largest cancers, and...
Flaws in CNBSS Are Vast, Impact on Screening Recommendations Is Nil
The recent report from the Canadian National Breast Screening Study (CNBSS)—published in BMJ and reviewed in The ASCO Post, early release online—concluded that annual mammography in women aged 40 to 59 does not result in a reduction in mortality from breast cancer beyond that of physical...
2014 Oncology Meetings
MARCH 31st Annual Miami Breast Cancer Conference®March 6-9 • Miami Beach, FloridaFor more information: www.gotoper.com/conferences/mbcc/meetings/31st-Annual-Miami-Breast-Cancer-Conference Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer...
APSHO: New Society for Advanced Practitioners
The Advanced Practitioner Society for Hematology and Oncology (APSHO) was launched during JADPRO Live. The Society is focused on meeting the unique educational and professional needs of this group of health-care professionals (nurse practioners, physician assistants, clinical nurse specialists,...
Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
Nearly 250 advanced practitioners assembled at the first annual JADPRO Live educational symposium in St. Petersburg, Florida, hosted by the Journal of the Advanced Practitioner in Oncology (JADPRO). Leaders from four prominent oncology organizations championed collaborative practice as not only...
FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously granted...
Expert Point of View: Jeffrey Miller, MD
Jeffrey Miller, MD, Professor of Medicine at the University of Minnesota and Deputy Director of the Masonic Cancer Clinic in Minneapolis, commented on the haploidentical hematopoietic stem cell transplantation studies presented at the American Society of Hematology meeting for The ASCO Post “The...
Expert Point of View: C. Kent Osborne, MD
At the San Antonio Breast Cancer Symposium, press briefing moderator C. Kent Osborne, MD, Director of the Dan Duncan Cancer Center at Baylor College of Medicine, Houston, predicted the findings of the study by Badwe et al could be practice-changing. “This is not to say that we shouldn’t perform...
Updated Information on Clinical Trials
Your patients can learn about clinical trials in a variety of ways at www.cancer.net/clinicaltrials. The articles available explain what clinical trials are, how they are used to learn more about cancer care, and how they are conducted. In addition, your patients can read a new article explaining...
Cancer.Net Expands Its Social Media Presence With Launch of Blog
In an effort to continue to bring patients and those who care about and for them the most timely, comprehensive cancer information, ASCO’s patient education website, Cancer.Net, has added a new interactive resource—the Cancer.Net Blog (www.cancer.net/blog). “We decided that a blog made sense for...
Cancer Progress in Jeopardy: Stories From the Front Lines
ASCO is exploring what is happening on the front lines in the laboratory and the clinic due to the shrinking federal funding for cancer research and clinical trials with a series of stories about oncologists. The series is posted on ASCO.org (www.asco.org/nihfunding). In the first article, Robert...
ASCO to Release Report on the State of Cancer Care in America
ASCO is committed to ensuring that Americans have access to high-quality, high-value cancer prevention and treatment services—and that all patients benefit fully from our nation’s investments in cancer research. In mid-March, the Society will be releasing The State of Cancer Care in America: 2014,...
Connecting to Conquer Cancer
Do you share our passion to conquer cancer? Connect with the Conquer Cancer Foundation online to receive up-to-the-minute news and events, researcher spotlights, videos, and updates on progress against cancer worldwide. Visit our website to learn more about our mission and the programs we support:...
Amplifying the Signal: Foundation Donor Takes His Advocacy Into the Twittersphere
Michael A. Thompson, MD, PhD, a Medical Oncologist for Aurora Cancer Care and the Medical Director of Early Cancer Research at Aurora Health Care in Wisconsin, has become something of an expert on the Conquer Cancer Foundation. It began in 2006, when he received a Conquer Cancer Foundation of ASCO...
Innovative I-SPY 2 Trial Yields First Results in Triple-Negative Breast Cancer
An innovative approach to streamlining the testing of novel agents in breast cancer has yielded some of its first results, which were reported at the 2013 San Antonio Breast Cancer Symposium.1 Adaptive Trial Design The veliparib/carboplatin plus standard neoadjuvant therapy regimen is currently...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage HER2-positive ...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
ASCO Applauds CVS Caremark’s Move to Stop Selling Tobacco
CVS Caremark recently announced that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of...
ASCO Supports Reinforcing FDA Capacity to Monitor Nation’s Drug Supply
“The GAO report identifies production lapses due to quality problems and constrained manufacturing capacity as being the central causes of the widespread incidence and persistence of drug shortages. “The report also emphasizes that the FDA has made significant progress in preventing shortages by ...
U.S. Government Accountability Office Issues Report on Drug Shortages
The U.S. Government Accountability Office (GAO) recently issued a report evaluating drug shortages and the associated public health threats, including prolonged duration of a disease, permanent injury, and death.1 This report follows a recommendation by GAO in 2011 that the U.S. Food and Drug...
Capecitabine Acceptable in Neoadjuvant Rectal Cancer Setting
As neoadjuvant therapy for rectal cancer, infusional fluorouracil (5-FU) and oral capecitabine achieve similar outcomes, and the addition of oxaliplatin confers no additional benefit, according to the mature results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 trial,...
Expert Point of View: Josep M. Llovet, MD
Josep M. Llovet, MD, Professor of Medicine at Mount Sinai Hospital, New York, commented on the findings reported by Faivre et al for The ASCO Post. “This is the first time a TGF-β inhibitor has been clinically tested in hepatocellular carcinoma, and the drug has a good safety profile. But this is a ...
Expert Point of View: Melanie B. Thomas, MD
Melanie B. Thomas, MD, Associate Director of Clinical Investigations and the Grace E. DeWolff Chair of Medical Oncology at the Medical University of South Carolina in Charleston, commented on the findings by Martin et al for The ASCO Post. “I think this study is exciting,” she said. “They were...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads (DEBIRI) given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable colorectal liver metastasis improved response rates, increased resectability, and prolonged hepatic progression–free survival in a...
Congress Agrees on Repeal of Sustainable Growth Rate
The U.S. Congress recently did something rarely seen on Capitol Hill: Leaders from both sides of the aisle agreed on a piece of legislation. On February 6, 2014, the House Energy and Commerce and Ways and Means Committees and the Senate Finance Committee announced its agreement on a bill—the SGR...
The Future of Biomedical Research
In January, Congress approved a $1 trillion appropriations bill for the rest of fiscal year 2014. While the new bill includes $29.9 billion for the National Institutes of Health (NIH)—$1 billion above FY2013 levels after sequestration—including $4.9 billion for the National Cancer Institute (NCI),...
Cancer Genes and Molecular Medicine: More Education Needed
I read with interest and concern the Perspective piece, “Cancer Genes, Promiscuity, and the National Debt,” which appeared on page 1 of the February 1st issue of The ASCO Post. The underlying premise of this wide-ranging and provocative article would appear to be that in a rush to implement...
‘Epidemic of Diagnosis’ of Thyroid Cancer Is Most Acute for Women
The epidemiology of the increased incidence of thyroid cancer, which has nearly tripled since 1975, “suggests that it is not an epidemic of disease but rather an epidemic of diagnosis,” Louise Davies, MD, MS, and H. Gilbert Welch, MD, MPH, concluded after analyzing trends in patients diagnosed with ...
Expect Questions About the Appropriate Use of Mohs Surgery
Mohs surgery can be an effective treatment option for nonmelanoma skin cancer, as well as for more rare but aggressive skin cancers. In addition, Mohs can be particularly helpful to treat patients with skin cancers that have recurred,” Brett M. Coldiron, MD, Clinical Associate Professor of...
Dermatologists Defend Mohs Surgery as Effective and Cost-Efficient With Low Rate of Recurrence
The headline, “Patients’ Costs Skyrocket, Specialists’ Incomes Soar,” aptly encapsulates the theme of a recent article in The New York Times,1 part of a series entitled, “Paying Till It Hurts.” “Oncologists benefit from the ability to mark up (and profit from) each dose of chemotherapy they...
National Colorectal Cancer Awareness Month
March is Colorectal Cancer Awareness Month, and the U.S. Department of Health and Human Services is committed to boosting public awareness about the importance of screening and treatment for colorectal cancer. Colorectal cancer poses the greatest risk to adults over age 50, and the U.S. Preventive...
Focus on the Virginia Association of Hematologists and Oncologists
The state of Virginia encompasses a vast area of 40,000 square miles and is divided into five regions: the Atlantic Coastal Plain, the Piedmont, the Blue Ridge, the Appalachian Ridge and Valley Region, and the Appalachian Plateau. The diverse geography of the state creates unique challenges for...
2014 Oncology Meetings
MARCH Society of Surgical Oncology Annual Cancer Symposium March 13 - 16 • Phoenix, ArizonaFor more information: www.surgonc.org 24th Annual Interdisciplinary Breast Cancer ConferenceMarch 15-19 • Las Vegas, NevadaFor more information: www.breastcare.org/ 9th European Breast Cancer ConferenceMarch ...
Major Cancer Milestones in History, From ASCO’s CancerProgress.Net
To help tell the story of progress against cancer, ASCO launched CancerProgress.Net in 2011. The site is intended as a resource for media, policymakers, oncologists, advocates, and the public. One central feature of the site is an interactive timeline of major milestones in cancer treatment,...
Music Therapy Yields Positive Effects on Coping Skills, Social Integration, and Family Environment for Young Patients With Cancer
A collaborative multisite study has found that teens and young adults undergoing stem cell transplantation as part of cancer treatment gain coping skills and resilience-related outcomes when participating with a board-certified music therapist in a therapeutic music protocol that includes writing...
How to Approach the Problem of CNS Metastasis in HER2-Positive Patients
Central nervous system (CNS) metastasis is a pervasive problem in the setting of HER2-positive breast cancer. While some patients can be managed easily, others are challenging, said Eric P. Winer, MD, Chief of the Division of Women’s Cancers and the Thompson Senior Investigator for Breast Cancer...
Radiopharmaceutical Receives Orphan Drug Designation
The radiopharmaceutical gallium-68 dotatate has been given orphan drug designation by the U.S. Food and Drug Administration and the European Medicines Agency for use as a diagnostic agent for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Gallium-68 dotatate is owned by...
Telemedicine: Efficiency in Cancer Screening and Outreach
As defined by the U.S. Health Resources and Services Administration teleheath is “the use of electronic information and telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health, and health administration.” It has ...
SSO/ASTRO Release Consensus Guideline on Breast Cancer Treatment
The Society of Surgical Oncology (SSO) has announced the availability of a comprehensive consensus guideline for physicians treating breast cancer developed to help reduce health-care costs and improve the course of treatment. Developed in conjunction with the American Society of Radiation Oncology ...
How Decoding the Genomes of Exceptional Responders Is Leading to More Effective Treatment for All Patients With Cancer
In 2012, David B. Solit, MD, Geoffrey Beene Chair and Director of the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, and his colleagues published the results of a phase II study1 of 45 patients with advanced bladder cancer. The purpose of the clinical...
President Obama’s FY 2015 Budget Proposal
[On March 4, 2014], President Obama released his proposed budget for fiscal year 2015. Among several cost-cutting measures designed to preserve Medicare solvency is a proposal to reduce reimbursement for life-sustaining cancer drugs. Currently, reimbursement to physicians for “Part B” drugs is...
St. Jude Children’s Research Hospital Committee Identifies Eight Palliative Care Priorities in Pediatric Oncology
About 2½ years ago, St. Jude Children’s Research Hospital in Memphis conducted a series of focus groups to better understand the palliative care priorities of bereaved parents. Their findings were never intended to be generalized, but rather to be used to formulate a strategic plan for an...
Neuro-Oncology Community Convenes in Workshop to Advance Imaging-Related Endpoints in Clinical Trials
Leaders from key cross-sections of the neuro-oncology community came together at a recent Brain Tumor Clinical Trial Endpoints Workshop to confront a critical challenge in developing and testing treatments for glioblastoma multiforme. Participants were able to adjourn the workshop with the...
Affordable Care Act to Cover Chemoprevention for Women at High Risk for Breast Cancer
On January 9, 2014, Kathleen Sebelius, Secretary of the Department of Health and Human Services, announced that under the Patient Protection and Affordable Care Act, women at increased risk of breast cancer will be entitled to preventive medications without incurring out-of-pocket costs (with the...
ASCO Addresses Changes in Medicare for 2014
Medicare patients make up 61% of new cancer cases in the United States, and as the population ages, that proportion is expected to rise to 70% by 2030. Over the past decade, the oncology community has been financially challenged by alterations in the Medicare payment system. To address the changes...
Impact of Delayed Initiation of Adjuvant Chemotherapy for Breast Cancer Varies by Tumor Subtype
The optimal time interval between surgery and initiation of adjuvant chemotherapy for early-stage breast cancer is not well established. Although most physicians aim to initiate adjuvant chemotherapy within a few weeks of surgery, clinical factors may cause delay. The influence of delay on relapse...
National Program to Screen Ashkenazi Women in Israel for BRCA Mutations Is Being Explored
Citing a World Health Organization report that lists Israel as having one of the highest rates of breast cancer in the world, The New York Times reported on a proposed screening program to identify women with BRCA1 and BRCA2 mutations.1 “A number of influential geneticists and cancer doctors from...
Stay Up-to-Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media to stay-up-to-date with the new resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device by subscribing to the Cancer.Net Blog at www.cancer.net/blog, or on...
ASCO’s Membership Grows to Nearly 35,000
ASCO has much to celebrate this year—namely, the Society’s 50th Anniversary. This occasion brings with it many other notable milestones. 2014 is a prime time to reflect on the remarkable growth of ASCO, from seven founders and 51 physicians at its first Annual Meeting to nearly 35,000 members...
